Tired of walking 10,000 steps a day? You can aim for this instead, research suggests
The study, led by Professor Melody Ding of the University of Sydney and published in The Lancet Public Health last month, analyzed dozens of studies that have been conducted worldwide since 2014 to consider the impacts of how many steps you take daily and other health outcomes. That includes developing diseases like cancer, type 2 diabetes, dementia, and depression, as well as dying from cancer or heart disease, a press release from the University explained.
Overall, according to Ding, the study found that aiming for 7,000 steps a day, far less than the aforementioned 10,000, is not only more realistic for some but just as beneficial.
Why you don't need to listen to the 10,000 daily steps marketing ploy
'We know daily step count is linked to living longer, but we now also have evidence that walking at least 7,000 steps a day can significantly improve eight major health outcomes – including reducing risk of cardiovascular disease, dementia and depressive symptoms,' she explained in the release.
For context, to reach 10,000 daily steps (advice that started as a marketing ploy), you would need to walk nearly five miles. To record 7,000 steps, you may need to walk only a little more than three miles. If 7,000 still feels difficult, Ding, like other health experts, suggests making small increases to your current step count. That could mean working toward an average of 2,000 steps a day to 4,000.
The study did, however, find notable benefits between walking 2,000 and 7,000 steps daily. For example, researchers found that walking 7,000 steps daily can reduce the risk of death by almost 50 percent. The risk of developing dementia drops by 38 percent, while the risk of type 2 diabetes drops by 22 percent.
What is the Presidential Fitness Test?
Previous research has shown there are plenty of benefits to walking fewer than 10,000 daily steps.
Dr. John Jakicic, a research professor in the Division of Physical Activity and Weight Management in the Department of Internal Medicine at KU School of Medicine, told Nexstar last year that more recent data suggests a goal of 8,000 steps a day can help prevent major chronic health conditions and extend your quality of life years.
Even fewer steps can still be beneficial. Dr. Tamanna Singh, co-director of the Cleveland Clinic's sports cardiology center, pointed to a 2023 study that suggested 2,600 to 2,800 daily steps were enough to produce health benefits, while a European study from 2022 found that increasing your step count by 1,000-step increments may lead to a 15% decrease in your risk of all-cause mortality.
Jakicic noted, though, that there is no firm answer on how many steps you should take in a day. That ultimately comes down to your personal goals.
'These studies just suggest a possible association – there is no direct causation here,' Singh explained. 'But the takeaway is that more physical activity – which we already know – leads to a healthier lifestyle.'
Instead, some health experts say to focus more on the clock than the pedometer when it comes to physical activity. The American Heart Association recommends that weekly, you should get 150 minutes of moderate-intensity physical activity or 75 minutes of vigorous-intensity physical activity.
A structured, timed workout isn't for everyone, Jakicic says — if you're 'exercise adverse,' you may prefer having a step goal.
'It gives a person credit for all the things that they're doing throughout the day,' he told Nexstar. 'And it can help them build a pattern of activity without them having to carve out 30, 45, 60 minutes at one time to go out and do this exercise.'
He adds that one method isn't better than the other, 'but they apply to people for different purposes.'
Whether it's a step count, a time-based goal, or just getting up and moving during the day, Singh says it's important to 'do what you can commit to and stay consistent.'
'The most important thing is to incorporate intentional physical activity most days of the week if not daily,' Singh notes. 'Your body does not care whether you are walking, jogging, swimming, biking, rowing, dancing – again, physical stimulus on a consistent basis will contribute to improvements in both cardiovascular and physical wellbeing.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
Researchers hope the findings will boost 'validity and credibility' for patients
People diagnosed with ME/chronic fatigue syndrome (CFS) have significant differences in their DNA compared to those without the condition, according to a 'groundbreaking' new study. Scientists said the findings offer the first robust evidence that genes contribute to a person's chance of developing the disease. The DecodeME study, said to be the largest of its kind in the world, uncovered eight areas of genetic code in people with ME/CFS (myalgic encephalomyelitis/chronic fatigue syndrome) that are markedly different to the DNA of people without the condition. Researchers hope the findings will boost 'validity and credibility' for patients, and help rebuff some of the stigma and lack of belief that exists around the condition. There is currently no diagnostic test or cure for ME/CFS, which is believed to affect around 67 million people worldwide, and very little is known about what causes it. A key feature of the condition is a disproportionate worsening of symptoms following even minor physical or mental activity, which is known as post-exertional malaise (PEM,) while other symptoms include pain, brain fog and extreme energy limitations that do not improve with rest. For the new study, researchers analysed 15,579 DNA samples from the 27,000 people with ME/CFS participating in DecodeME, described as the world's largest data set of people with the disease. The eight regions of DNA where scientists found genetic differences involve genes linked to the immune and nervous systems. At least two of the genetic signals relate to how the body responds to infection, which researchers said aligns with long-standing patient reports that the onset of symptoms often followed an infectious illness. Professor Chris Ponting, DecodeME investigator from the University of Edinburgh, said: 'This is a wake-up call. These extraordinary DNA results speak the language of ME/CFS, often recounting people's ME/CFS symptoms. 'DecodeME's eight genetic signals reveal much about why infection triggers ME/CFS and why pain is a common symptom. 'ME/CFS is a serious illness and we now know that someone's genetics can tip the balance on whether they are diagnosed with it.' As a person's DNA does not change over time, experts say the genetic signals identified would not have developed because of ME/CFS and are therefore likely to reflect the causes of the disease. Populations used in the initial study were limited to those from European ancestries. READ MORE: We must protect chronic pain management services: it's not just about 'old people' I suffer from chronic fatigue syndrome. I know it's real - so why don't doctors? The sorry tale of Scotland's chronic pain crisis DecodeME research studying DNA data from all ancestries is ongoing. ME/CFS, thought to affect around 404,000 people in the UK, affects more females than males, although researchers found nothing to explain why this is the case. The DecodeME team is now calling on researchers from around the world to access its 'rich' dataset and help drive forward targeted studies into ME/CFS. Sonya Chowdhury, chief executive of Action for ME and a DecodeME co-investigator, said: 'These results are groundbreaking. 'With DecodeME, we have gone from knowing next to nothing about the causes of ME/CFS, to giving researchers clear targets.' She also hopes the discoveries will help change the way the condition is viewed. Ms Chowdhury said: 'This really adds validity and credibility for people with ME. 'We know that many people have experienced comments like ME is not real, or they've been to doctors and been disbelieved or told that it's not a real illness. 'Whilst things have changed and continue to change, that is still the case for some people and we hear that repeatedly as a charity. 'Being able to take this study into the treatment room and say there are genetic causes that play a part in ME is going to be really significant for individuals. 'It will rebuff that lack of belief and the stigma that exists.' The findings have been reported in a pre-print publication, or unpublished study. During a media briefing about the study, researchers were asked about similarities between the symptoms of long Covid and ME/CFS. Prof Ponting said: 'It's very clear that the symptomology between long Covid and ME is highly similar. 'Not for everyone but there are substantial similarities but as a geneticist the key question for me is are there overlapping genetic factors, and we haven't found that in DECode ME with the methods that we've employed. 'One of the key things that we're doing is enabling others to use their different approaches to ask and answer the same question.' DecodeME is a collaboration between the University of Edinburgh, the charity Action for ME, the Forward ME alliance of charities, and people with ME/CFS. It is funded by the Medical Research Council and National Institute for Health and Care Research.
The Hill
4 hours ago
- The Hill
Legionnaires' outbreak grows: What are the disease's first symptoms?
(NEXSTAR) – Three people have died and at least 67 have been infected as a cluster of Legionnaires' disease cases in New York City continues to spread. The case count has ballooned since the bacteria that causes Legionnaires' started sickening people in late July. City health officials link the outbreak in Central Harlem to cooling towers, structures containing water and a fan that are used to cool buildings. They said 11 of these towers initially tested positive for a type of bacteria that causes Legionnaires', but the problem has been fixed. Three dead as Legionnaires' cluster spreads in NYC Legionnaires' disease is a type of pneumonia caused by bacteria that grows in warm water. It can spread through water systems, like showerheads, hot tubs or cooling towers for central AC. People often get the disease by inhaling mist from contaminated water, but it is not spread from person to person. What are the symptoms of Legionnaires' disease? Once exposed to the bacteria, symptoms can take anywhere from two days to two weeks to show up, according to the Centers for Disease Control and Prevention. The symptoms of Legionnaires' overlap with other pneumonia symptoms: cough, fever, headaches, muscle aches and shortness of breath. In the most serious cases, Legionnaires' can cause lung failure or death. The pneumonia can be confirmed with a chest X-ray, but a lab test of a patient's urine or phlegm would be able to confirm if the pneumonia is caused by Legionella bacteria. Most people exposed to the bacteria don't get sick, the CDC notes, but those with pre-existing conditions can suffer serious symptoms or death. About 1 in 10 people who gets the disease will die due to complications, the CDC says. What is the treatment for Legionnaires' disease? Those in the neighborhoods of New York City impacted by the outbreak (ZIP codes 10027, 10030, 10035, 10037, 10039 and surrounding areas) should contact their doctor if they have any of the symptoms described above. That's especially true for people 50 and older, people who smoke and people with chronic lung conditions, as they are more susceptible to serious consequences. Once identified, the disease can be treated with antibiotics.
Business Wire
6 hours ago
- Business Wire
Northwell's Staten Island University Hospital Performs First U.S. Procedure With New BioHealx Device for Complex Anal Fistulas
STATEN ISLAND, N.Y.--(BUSINESS WIRE)--Northwell's Staten Island University Hospital (SIUH) is the first medical center in the United States to perform surgery using the newly FDA-cleared BioHealx ®Anal Fistula Device - offering new hope to patients suffering from complex and often debilitating anal fistulas. The procedures were performed by colorectal surgeons Poppy Addison, MD, and Giovanni Bonomo, MD, director of colorectal surgery. The BioHealx device, developed by Irish-based Signum Surgical, represents a significant advancement in the treatment of complex anal fistulas, notoriously difficult to treat with current surgical options. The minimally invasive, absorbable implant is designed to close fistula tract as it traverses the anal sphincter complex, without involving any significant disruption of the anorectal anatomy. Early European data demonstrated an 84% success rate, far exceeding traditional approaches that often have success rates closer to 60% and are associated with the need for multiple procedures to finally achieve healing. 'Historically, these surgeries have been long, complex, traumatic to the anorectum and carried the risk of recurrence and incontinence,' said Dr. Bonomo. 'The BioHealx device is intuitive, efficient, and minimizes surgical trauma. If we can replicate the European outcomes, this could set a new standard of care in fistula treatment.' Approximately, 90,000 complex anal fistula procedures are performed yearly. These fistulas predominantly affect men between ages 18 and 50, and disrupts their quality of life due to anal pain, foul-smelling drainage, and recurrent infection. Fistulas can recur even after what appears to be healing at the skin level due to persistence of the transsphincteric fistula tract, and many patients undergo multiple interventions before finding relief. 'Rectal fistulas are under-researched and have lacked a reliable, standardized solution,' said Dr. Addison. 'This device has the potential to optimize care, shorten recovery, and reduce recurrence, all while preserving continence, which is a critical concern for our patients.' Before surgery, a seton drain is placed to help mature the fistula tract and to provide for clear identification of the internal fistula opening. During the BioHealx procedure, the seton is removed, the tract is brushed clean, and a small flap is created to expose the internal sphincter at the location of internal opening. The corkscrew-shaped BioHealx implant is then inserted to compress the tissue around the fistula tract as it traverses the width of the sphincter complex to deliver primary healing by direct tissue apposition. The flap is closed over the internal opening and internal anal sphincter, while the outer tract is partially opened for optimal drainage - all without damaging the sphincter muscle nor disrupting the anal canal. The implant itself is made from bioabsorbable polylactic glycolic acid and naturally dissolves in the body within six to twelve months, leaving no permanent material behind. The inspiration for the BioHealx device dates back to 2013 when engineers Eoin Bambury and Moshe Zilversmit, co-founders of Signum Surgical, met during a government-sponsored fellowship in Ireland. After observing the repeated failure of traditional surgeries to treat anal fistulas, often requiring four or more operations, they launched Signum Surgical in 2016 to develop a better solution. 'The key was identifying the failure of primary healing of the transsphincteric portion of the fistula tract as the root cause of surgical failure,' said Bambury. 'Our goal was to close it effectively without damaging the anal canal nor the anal sphincter. After years of research, clinical trials, and design refinement, we're proud to see our work helping patients here in the U.S.' SIUH's successful completion of the first U.S. procedures using the BioHealx device represents a critical milestone in the adoption of innovative, patient-centered technology across Northwell Health. 'Northwell has always championed advanced technologies that improve outcomes and quality of life,' said Dr. Bonomo. 'This is the kind of breakthrough that can change how we treat complex anal fistulas nationwide.' Drs. Bonomo and Addison will continue evaluating patient outcomes to help guide future adoption and research of the BioHealx procedure. With a shorter learning curve than many other surgical techniques, the team believes the procedure can be easily adopted across the entire system. 'We're incredibly optimistic,' said Dr. Addison. 'This device doesn't burn any bridges - it's safe, effective, and easy to use. If it doesn't work, patients still have all their future options with essentially normal anorectal anatomy. But if it does, it can spare them years of painful, frustrating treatments.'
